Covance | Jotup

PsychoGenics Strengthens Executive Team to Boost CNS Drug Discovery and CRO Capabilities

Retrieved on:

Tuesday, June 28, 2022

Mental Health, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Army of the United States, PTSD, University of London, Migraine, Patient, Schizophrenia, CEO, Research, Accounting, Therapy, Business administration, Northwestern University, Contract research organization, Microdialysis, Connective tissue disease, COO, CNS, Eli Lilly, Drug discovery, Company, Industry, ALS, Eli Lilly and Company, Master of Business Administration, Economics, Icahn School of Medicine at Mount Sinai, Mount Sinai, Pain, Depression, CRO, Development, Partnership, Kellogg School, Charles River Laboratories, University, Lists of diseases, Muscular dystrophy, Epilepsy, Sunovion, Ripon College, Psychology, Leadership, Chicago (franchise), Electrophysiology, Molecular biology, EEG, Autism, Management, Pharmaceutical industry, Neuroscience, Covance

Dr. Bleakman will lead the Companys drug discovery team and strategically advance the multiple research programs in development.

Key Points:

Dr. Bleakman will lead the Companys drug discovery team and strategically advance the multiple research programs in development.
He is an internationally recognized neuroscientist and expert in drug discovery and development with over 30 years of experience.
Both our AI-enabled discovery engine and CRO are unmatched in todays industry, and our leadership team is laser-focused on growing our business, supporting our partners needs and challenging existing drug discovery norms to deliver improved CNS treatment options.
PsychoGenics Inc. and its discovery arm, PGI Drug Discovery LLC (collectively known as PsychoGenics), have pioneered the translation of rodent behavioral and physiological responses into robust, high-throughput and high-content phenotyping.

Adare Pharma Solutions Announces Appointment of Tom Sellig as Chief Executive Officer

Retrieved on:

Thursday, January 6, 2022

LAWRENCEVILLE, N.J., Jan. 6, 2022 /PRNewswire/ -- Adare Pharma Solutions ("Adare"), a global, technology-driven contract development and manufacturing organization (CDMO), today announced the appointment of Tom Sellig as Chief Executive Officer (CEO). Sellig, a 30-year veteran of the pharmaceutical and life sciences industries, will lead the organization in supporting pharmaceutical companies in the development and manufacturing of transformative medicines that improve patient health and outcomes.

Key Points:

LAWRENCEVILLE, N.J., Jan. 6, 2022 /PRNewswire/ --Adare Pharma Solutions ("Adare"), a global, technology-driven contract development and manufacturing organization (CDMO), today announced the appointment of Tom Sellig as Chief Executive Officer (CEO).
Adare offers technology-driven solutions to solve pharmaceutical companies' challenges from product development to commercial scale manufacturing and packaging.
"We are thrilled to welcome Tom to Adare," said Nathan Every, General Partner at Frazier Healthcare Partners, a financial sponsor of Adare.
Adare Biome is a division of Adare Pharma Solutions focused on postbiotic production through a proprietary ECHO fermentation process.

Adare Pharma Solutions Announces Appointment of Tom Sellig as Chief Executive Officer

Retrieved on:

Thursday, January 6, 2022

LAWRENCEVILLE, N.J., Jan. 6, 2022 /PRNewswire/ -- Adare Pharma Solutions ("Adare"), a global, technology-driven contract development and manufacturing organization (CDMO), today announced the appointment of Tom Sellig as Chief Executive Officer (CEO). Sellig, a 30-year veteran of the pharmaceutical and life sciences industries, will lead the organization in supporting pharmaceutical companies in the development and manufacturing of transformative medicines that improve patient health and outcomes.

Key Points:

LAWRENCEVILLE, N.J., Jan. 6, 2022 /PRNewswire/ --Adare Pharma Solutions ("Adare"), a global, technology-driven contract development and manufacturing organization (CDMO), today announced the appointment of Tom Sellig as Chief Executive Officer (CEO).
Adare offers technology-driven solutions to solve pharmaceutical companies' challenges from product development to commercial scale manufacturing and packaging.
"We are thrilled to welcome Tom to Adare," said Nathan Every, General Partner at Frazier Healthcare Partners, a financial sponsor of Adare.
Adare Biome is a division of Adare Pharma Solutions focused on postbiotic production through a proprietary ECHO fermentation process.

Haematologic Technologies Announces Joe Flynn as Chief Commercial Officer

Retrieved on:

Thursday, January 6, 2022

ESSEX JUNCTION, Vt., Jan. 6, 2022 /PRNewswire/ --Haematologic Technologies ("HT"), a global leader in large molecule analytical services and plasma reagents reagents, today announced the appointment of Joe Flynn as Chief Commercial Officer.

Key Points:

ESSEX JUNCTION, Vt., Jan. 6, 2022 /PRNewswire/ --Haematologic Technologies ("HT"), a global leader in large molecule analytical services and plasma reagents reagents, today announced the appointment of Joe Flynn as Chief Commercial Officer.
Before joining HT, Joe created and lead the commercial team at Inotiv, with responsibility for the sales, marketing, client experience and program management teams.
Before Inotiv, Joe held operational and commercial roles of increasing responsibility at Covance.
"HT has developed a very loyal client base and they are known for great science with high quality client interactions," said Joe Flynn.

Crown Bioscience Invests in Commercial Leadership

Retrieved on:

Tuesday, July 20, 2021

Oncology, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Corning Inc., Covance, LabCorp, Eurofins Scientific, Life sciences, Companies, Industry economics)

Crown Bioscience, a JSR Life Sciences company, today announces the appointment of Alex Slater as Vice President of Business Development, North America and Europe.

Key Points:

Crown Bioscience, a JSR Life Sciences company, today announces the appointment of Alex Slater as Vice President of Business Development, North America and Europe.
In previous roles, he has served as Global VP for Business Development at Eurofins and held multiple sales leadership positions at Covance/LabCorp.
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, immuno-oncology and inflammatory disorders.
With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.

Labcorp And OmniSeq Launch INSIGHT℠, Next-Generation Sequencing Platform to Advance Precision Oncology

Retrieved on:

Monday, June 14, 2021

Burlington, North Carolina, LabCorp, Covance, Precision medicine, Dynacare, Oncology, Life sciences, Articles, Industry economics)

The test is designed to advance precision oncology and improve patient outcomes, as part of Labcorp's commitment to empower better health decisions for patients through the addition of cutting-edge diagnostic tools in precision medicine.

Key Points:

The test is designed to advance precision oncology and improve patient outcomes, as part of Labcorp's commitment to empower better health decisions for patients through the addition of cutting-edge diagnostic tools in precision medicine.
OmniSeq INSIGHT is available to U.S.-based clinicians exclusively through Labcorp, and across Canada through Dynacare, a Labcorp company.
"We are excited to advance our partnership with Labcorp, continuing to provide increased access to oncology care for patients leveraging Labcorp's extensive footprint and oncology experience," said Margot Schoenborn, CEO of OmniSeq.
Learn about Covance by Labcorp at www.Covance.com , and Labcorp at www.Labcorp.com , or follow us on LinkedIn and Twitter @Labcorp.

Global Medical Devices Outsourcing Market Report 2021: Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2019-2029 - ResearchAndMarkets.com

Retrieved on:

Wednesday, June 9, 2021

Medical devices, Health, Articles, Business, Economy, Economic globalization, Offshoring, Information technology management, International business, International trade, Outsourcing, Medical device, Covance, On-demand outsourcing

The "Medical Devices Outsourcing Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Medical Devices Outsourcing Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering.
Outsourcing of medical devices manufacturing has become a pervasive aspect of medical device industry with every company are choosing outsourcing over in-house manufacturing.
In 2020, contract manufacturing held the largest share in the global medical devices outsourcing market and projected to be the dominant marker during the forecast period.
The key players currently engaged in medical devices outsourcing market include Covance, Inc., Pharmaceutical Product Development, LLC.

Labcorp to Expand Bioanalytical Services With Integrated Laboratory in Singapore

Retrieved on:

Wednesday, May 19, 2021

Health, Hospitals, Other Health, General Health, Clinical trials, Pharmaceutical, Biotechnology, Life sciences, Natural sciences, Contract research organizations, Analytical chemistry, Medicine, Bioanalysis, Pharmacokinetics, Toxicology, Covance, LabCorp, Biomarker

\xe2\x80\x9cWe are thrilled to expand services in this area and enhance the options available to those we serve.

Key Points:

\xe2\x80\x9cWe are thrilled to expand services in this area and enhance the options available to those we serve.
The new laboratory will provide expedited turnaround time for our clients and enhance Covance by Labcorp\xe2\x80\x99s ability to deliver for the Asia-Pacific region.\xe2\x80\x9d\nThe new bioanalytical laboratory in Singapore will support the development of both small and large molecular entities while providing a complete range of regulated and non-regulated bioanalytical services.
Bioanalytics is a quantitative measure of drugs and metabolites in biological samples such as blood, serum, tissue and plasma.
The laboratory will offer Good Laboratory Practice and Good Clinical Practice-compliant bioanalysis, liquid chromatography-mass spectometry and immunochemistry platforms, as well as discovery and clinical biomarker analytical services.

n-Lorem Foundation, ChemGenes Announce Collaboration to Support Manufacturing of Individualized Treatments for Patients with Ultra-Rare Diseases

Retrieved on:

Tuesday, April 13, 2021

\xe2\x80\x9cChemGenes joins Ionis Pharmaceuticals, Biogen, Ultragenyx Pharmaceutical, Charles River Labs, Covance by Labcorp, and Korea Institute of Toxicology (KIT) as industry partners supporting our efforts at n-Lorem.

Key Points:

\xe2\x80\x9cChemGenes joins Ionis Pharmaceuticals, Biogen, Ultragenyx Pharmaceutical, Charles River Labs, Covance by Labcorp, and Korea Institute of Toxicology (KIT) as industry partners supporting our efforts at n-Lorem.
We are very pleased to join n-Lorem in this endeavor as a donor and a collaborator,\xe2\x80\x9d said Dr. Suresh Srivastava, President, ChemGenes Corporation.
ASOs are short strands of modified DNA that can specifically target the transcripts of a defective gene to correct the abnormality.
We have consistently been a strong partner to researchers engaged in the field of DNA/RNA synthesis for 40 years.

n-Lorem Foundation Partners with Ultragenyx to Bolster Development of Personalized Medicines for Patients with Ultra-Rare Diseases

Retrieved on:

Monday, April 5, 2021

n-Lorem Foundation is the first and only foundation with a mission to provide potentially life-saving treatments to patients who have diseases caused by extremely rare mutations (1 to 30 patients worldwide) for free, for life, by coupling advanced genomic diagnostics with antisense oligonucleotides (ASOs) medicines.

Key Points:

n-Lorem Foundation is the first and only foundation with a mission to provide potentially life-saving treatments to patients who have diseases caused by extremely rare mutations (1 to 30 patients worldwide) for free, for life, by coupling advanced genomic diagnostics with antisense oligonucleotides (ASOs) medicines.
Ultragenyx joins Ionis Pharmaceuticals, Biogen, Charles River Labs, Covance by Labcorp, and Korea Institute of Toxicology (KIT) as industry partners supporting our efforts at n-Lorem.
To learn more about the n-Lorem Foundation, visit www.nlorem.org , and follow us on Twitter , Facebook , LinkedIn and YouTube .
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases.